ICU Medical price target raised to $198 from $147 at KeyBanc

KeyBanc analyst Brett Fishbin raised the firm’s price target on ICU Medical to $198 from $147 and keeps an Overweight rating on the shares. The firm is encouraged by significant year-to-date progress in demonstrating improved operational stability. Guidance has remained conservative, and KeyBanc thinks it is positioned for continued outperformance into the second half of 2024. The firm also sees multiple upside drivers in place for 2025.